HCP
BNTX icon

Hexagon Capital Partners’s BioNTech BNTX Stock Holding History

Hexagon Capital Partners’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-76
Closed -$6.92K – 287
2025
Q1 		$6.92K Buy
76
+14
+23% +$1.57K ﹤0.01% 1075
2024
Q4 		$7.07K Buy
62
+27
+77% +$3.08K ﹤0.01% 1112
2024
Q3 		$4.16K Hold
35
– – ﹤0.01% 1095
2024
Q2 		$2.81K Sell
35
-35
-50% -$3.2K ﹤0.01% 1107
2024
Q1 		$6.46K Sell
70
-87
-55% -$8.34K ﹤0.01% 955
2023
Q4 		$16.6K Buy
157
+5
+3% +$504 ﹤0.01% 700
2023
Q3 		$16.5K Buy
152
+86
+130% +$9.51K ﹤0.01% 620
2023
Q2 		$7.12K Sell
66
-7
-10% -$787 ﹤0.01% 830
2023
Q1 		$9.09K Sell
73
-24
-25% -$3.29K ﹤0.01% 752
2022
Q4 		$14.6K Sell
97
-13
-12% -$2K ﹤0.01% 630
2022
Q3 		$15K Buy
110
+75
+214% +$11.5K ﹤0.01% 655
2022
Q2 		$5K Buy
+35
New +$5.35K ﹤0.01% 788

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hexagon Capital Partners's BNTX Position: Q2 2025 in Review

Hexagon Capital Partners sold out of BioNTech (BNTX) in Q2 2025, closing a stake of 76 shares — an estimated $6.92K sold.

Hexagon Capital Partners first reported a position in BNTX in Q2 2022 and held it in 12 quarters. The position peaked at $16.6K in Q4 2023. 258 funds tracked by Wall St. Rank hold BNTX as of Q2 2025.

  • Hexagon Capital Partners reported no remaining BioNTech position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 76 BioNTech shares in Q2 2025, an estimated $6.92K.
  • Hexagon Capital Partners first reported a position in BioNTech in Q2 2022 and held it in 12 quarters.
  • Hexagon Capital Partners's BioNTech position peaked at $16.6K in Q4 2023.
  • 258 funds tracked by Wall St. Rank held BioNTech as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.